Embolism News and Research

RSS

Phase III EINSTEIN trial program: XARELTO reduces risk of DVT and PE

Janssen Pharmaceuticals, Inc. announced today a newly published, pooled analysis of the Phase III EINSTEIN trial program, showing XARELTO (rivaroxaban) is as effective as the standard of care in reducing the risk of deep vein thrombosis and pulmonary embolism in people with symptomatic DVT or PE, while reducing the incidence of major bleeding by 46 percent.

21 Sep 2013

Asthma exacerbates PE risk

Data from Taiwan show that asthma is associated with a significant increase in the risk for pulmonary embolism, particularly in patients who experience exacerbations.

5 Sep 2013

Hokusai-VTE findings provide fresh insight into patients with pulmonary embolism

In the treatment of venous thromboembolism (VTE), the oral anticoagulant edoxaban resulted in equal efficacy and better safety compared to standard warfarin when either drug was used with initial low molecular weight heparin (LMWH), according to the results of the Hokusai-VTE trial.

5 Sep 2013

Multiple risk factors eliminate impact of AF on stroke risk, but more research is needed

Dr Benn Christiansen said: "We know that atrial fibrillation increases the risk of ischemic stroke. And in patients with atrial fibrillation or previous ischemic stroke, the risk of stroke increases with the number of risk factors.

5 Sep 2013

"Risk calculator" enables doctors to estimate risk of venous thrombosis

In Austria, around 15,000 people a year develop a venous thrombosis, the occlusion of a vein that can result in a pulmonary embolism. A clot breaks free from a vein and travels via the bloodstream to the lungs, where it blocks vessels.

14 Aug 2013

Immune function restored in spinal injured mice

In a new study, researchers at The Center for Brain and Spinal Cord Repair at The Ohio State University Wexner Medical Center show that is possible to restore immune function in spinal injured mice.

7 Aug 2013

Clot-inhibiting drug apixaban shows added benefits in adults with non-valvular atrial fibrillation

The clot-inhibiting drug apixaban (trade name: Eliquis) has been approved in Germany since November 2012 for the prevention of embolism and stroke in adults with non-valvular atrial fibrillation.

3 Aug 2013

August edition of NPS RADAR includes reviews for new medicines listed on PBS

The 10th anniversary edition of NPS RADAR contains reviews for new medicines listed on the Pharmaceutical Benefits Scheme including rivaroxaban (Xarelto), rotigotine patches (Neupro) and mifepristone (Mifepristone Linepharma) followed by misoprostol (GyMiso).

1 Aug 2013

Inhalable gene therapy may restore function of crucial enzyme to reverse deadly PAH

The deadly condition known as pulmonary arterial hypertension (PAH), which afflicts up to 150,000 Americans each year, may be reversible by using an inhalable gene therapy, report an international team of researchers led by investigators at the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai.

31 Jul 2013

NPS MedicineWise finds little or no clinical benefit in switching to rivaroxaban for stroke prevention

With oral anticoagulant rivaroxaban set to be subsidised under the Pharmaceutical Benefits Scheme (PBS) for preventing stroke, NPS MedicineWise is urging people to talk to their doctor before stopping or making any changes to their anticoagulant medicines.

30 Jul 2013

ACC report helps clinicians optimize appropriate use of noninvasive vascular tests

A new report issued today by the American College of Cardiology (ACC) and developed in collaboration with 10 other leading professional societies provides detailed criteria to help clinicians optimize the appropriate use of certain noninvasive vascular tests when caring for patients with known or suspected disorders of the venous (veins) system.

20 Jul 2013

Weekend reading: Doctors who decide, death desires, and decisions

On the last week of April earlier this year, a small committee of doctors met quietly in a midsized ballroom at the Renaissance Hotel in Chicago. There was an anesthesiologist, an ophthalmologist, a radiologist, and so on-;thirty-one in all, each representing their own medical specialty society, each a heavy hitter in his or her own field.

12 Jul 2013

Bristol-Myers Squibb, Pfizer announce FDA acceptance of Eliquis sNDA for review

Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration has accepted for review a Supplemental New Drug Application for Eliquis (apixaban), for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, in adult patients who have undergone hip or knee replacement surgery.

11 Jul 2013

Boehringer submits application to EMA for use of Pradaxa for treatment of acute DVT, PE

Boehringer Ingelheim today announced the submission of an application to the European Medicines Agency (EMA) for use of Pradaxa (dabigatran etexilate) for the treatment of acute deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE.

24 Jun 2013

Study shows patients with avascular necrosis have turned to stem cell therapy for aid

Stem cells have long been touted as the next big thing. Well just maybe, it is here. According to Dr. Dennis Lox, some patients with a disorder of the bone called avascular necrosis (AVN), have turned to stem cell therapy for aid.

15 Jun 2013

Research: Bevacizumab fails to increase overall survival for glioblastoma patients

The angiogenesis inhibitor bevacizumab (Avastin) failed to increase overall survival (OS) or statistically significant progression-free survival (PFS) for glioblastoma patients in the frontline setting, according to research led by researchers at The University of Texas MD Anderson Cancer Center.

3 Jun 2013

Standard strategies to prevent lethal blood clots more effective than temporary placement of filters

The temporary placement of umbrella-like, metal mesh filters in abdominal veins to stop potentially lethal blood clots from traveling to the lungs during and after weight loss surgery may actually increase the risk of death in morbidly obese patients, according to new Johns Hopkins research.

30 May 2013

Study reports liver donors face mortality risk with LDLT

A study published in Liver Transplantation, a journal of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, reports that donor mortality is about 1 in 500 donors with living donor liver transplantation (LDLT).

26 Apr 2013

Living liver donors at risk from life-threatening “near-miss” events?

25 Apr 2013

Perosphere, Daiichi Sankyo sign clinical trial agreement

Perosphere Inc. and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that they have entered into a clinical trial agreement under which Daiichi Sankyo will support and co-sponsor a phase 1 clinical study testing the safety, tolerability and effectiveness of PER977 to reverse the anticoagulant activity of edoxaban, Daiichi Sankyo's investigational oral, once-daily, direct factor Xa-inhibitor.

25 Apr 2013

Embolism News and Research

Phase III EINSTEIN trial program: XARELTO reduces risk of DVT and PE

Asthma exacerbates PE risk

Hokusai-VTE findings provide fresh insight into patients with pulmonary embolism

Multiple risk factors eliminate impact of AF on stroke risk, but more research is needed

"Risk calculator" enables doctors to estimate risk of venous thrombosis

Immune function restored in spinal injured mice

Clot-inhibiting drug apixaban shows added benefits in adults with non-valvular atrial fibrillation

August edition of NPS RADAR includes reviews for new medicines listed on PBS

Inhalable gene therapy may restore function of crucial enzyme to reverse deadly PAH

NPS MedicineWise finds little or no clinical benefit in switching to rivaroxaban for stroke prevention

ACC report helps clinicians optimize appropriate use of noninvasive vascular tests

Weekend reading: Doctors who decide, death desires, and decisions

Bristol-Myers Squibb, Pfizer announce FDA acceptance of Eliquis sNDA for review

Boehringer submits application to EMA for use of Pradaxa for treatment of acute DVT, PE

Study shows patients with avascular necrosis have turned to stem cell therapy for aid

Research: Bevacizumab fails to increase overall survival for glioblastoma patients

Standard strategies to prevent lethal blood clots more effective than temporary placement of filters

Study reports liver donors face mortality risk with LDLT

Living liver donors at risk from life-threatening “near-miss” events?

Perosphere, Daiichi Sankyo sign clinical trial agreement

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Latest News